Larimar Therapeutics Q3 2026 Results

Cover art for Larimar Therapeutics Q3 2026 Results

TL;DR: Larimar Therapeutics Inc. posted a $31.1M net loss for Q3 2026, narrowing per-share loss to $0.29 from $0.61 in Q3 2025. Larimar Therapeutics reports narrower Q3 2026 loss as it advances rare disease therapies. Larimar Therapeutics Inc. posted a net loss of $31.1M for Q3 2026. The per-share loss narrowed to $0.29 from $0.61 in Q3 2025, a 52.5% improvement.

AlphaStreet NewsdeskNov 16, 2026

From · · · 40s

TL;DR: Larimar Therapeutics Q3 2026 Results

Larimar Therapeutics reports narrower Q3 2026 loss as it advances rare disease therapies.

Larimar Therapeutics Inc. posted a $31.1M net loss for Q3 2026, narrowing per-share loss to $0.29 from $0.61 in Q3 2025. Larimar Therapeutics reports narrower Q3 2026 loss as it advances rare disease therapies. Larimar Therapeutics Inc. posted a net loss of $31.1M for Q3 2026. The per-share loss narrowed to $0.29 from $0.61 in Q3 2025, a 52.5% improvement.

  • Q3 2026 Financial Results
  • Per-Share Loss Narrowed
  • Analyst Support

Read the story version — the same reporting as a swipeable deck of 3 cards.

Read the original on Alphastreet - Earnings Decoded. Market Intelligence Delivered

How we make summaries

React

Sign in to react and comment.

Comments (0)

Life is short. Keep it sweet. Respect others' opinions and be kind!

    Recommended next

    More decks on earnings and related topics.